5β-spirostane

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 5β-spirostane
• 英文别名: 5beta-Spirostan；(1R,2S,4S,6R,7S,8R,9S,12S,13S,18S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]
• 化学式: C₂₇H₄₄O₂
• 分子量: 400.645
• InChiKey: INLFWQCRAJUDCR-XPCNEENDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.2
• 重原子数：
  29
• 可旋转键数：
  0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• ANTIDEPRESSANT COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF
  申请人：Shanghai Institute of Materia Medica, Chinese Academy of Sciences

  公开号：EP3564253A1

  公开（公告）日：2019-11-06

  An antidepressant steroid compound and a preparation method and an application thereof; the structure of said compound is shown in formula (I), and the definition of each substituent is as described in the description and claims. Compound of the present invention may be used in the prevention, treatment, therapy or alleviation of a plurality of diseases and conditions such as depression.

  一种抗抑郁类固醇化合物及其制备方法和应用；所述化合物的结构如式（I）所示，各取代基的定义如说明书和权利要求书所述。本发明的化合物可用于预防、治疗、治疗或缓解多种疾病和病症，如抑郁症。
• DERIVATIVE BASED ON COMMON ANEMARRHENAE RHIZOME SARSASAPOGENIN STRUCTURE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
  申请人：Phytovent Biopharma

  公开号：EP3858849A1

  公开（公告）日：2021-08-04

  The present invention relates to a derivative of sarsasapogenin having a structure of formula I, The present invention also provides a pharmaceutical composition of the aforementioned derivative of sarsasapogenin and use thereof. By systematic modification and derivatization of sarsasapogenin structure in combination with inhibitory activity assays on tumor cells, the inventor surprisingly found that many derivative compounds have excellent inhibitory activity on tumor cells, particularly high inhibitory activity on the growth of various brain tumor cells, having potential wide application and tremendous value in treating various cancers, making up for the deficiency of modified derivatives of sarsasapogenin in the prior art and having important scientific and commercial application value.

  本发明涉及一种具有式 I 结构的菝葜皂苷元衍生物、 本发明还提供了上述菝葜皂苷元衍生物的药物组合物及其用途。通过对菝葜皂苷元结构的系统修饰和衍生化，结合对肿瘤细胞的抑制活性实验，本发明人惊喜地发现，许多衍生化合物对肿瘤细胞具有极好的抑制活性，特别是对各种脑肿瘤细胞的生长具有很高的抑制活性，在治疗各种癌症方面具有潜在的广泛应用和巨大价值，弥补了现有技术中菝葜皂苷元修饰衍生物的不足，具有重要的科学和商业应用价值。
• Antidepressant compound and preparation method and application thereof
  申请人：SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

  公开号：US11142543B2

  公开（公告）日：2021-10-12

  An antidepressant steroid compound and a preparation method and an application thereof; the structure of said compound is shown in formula (I), and the definition of each substituent is as described in the description and claims. Compound of the present invention may be used in the prevention, treatment, therapy or alleviation of a plurality of diseases and conditions such as depression.

  一种抗抑郁类固醇化合物及其制备方法和应用；所述化合物的结构如式（I）所示，各取代基的定义如说明书和权利要求书所述。本发明的化合物可用于预防、治疗、治疗或缓解多种疾病和病症，如抑郁症。
• [EN] DERIVATIVE BASED ON COMMON ANEMARRHENAE RHIZOME SARSASAPOGENIN STRUCTURE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF<br/>[FR] DÉRIVÉ BASÉ SUR UNE STRUCTURE COMMUNE DE SARSASAPOGÉNINE DE RHIZOME D'ANEMARRHENAE, COMPOSITION PHARMACEUTIQUE ET UTILISATION ASSOCIÉE<br/>[ZH] 基于知母菝契皂苷元结构的衍生物、药物组合物及其应用
  申请人：PHYTOVENT BIOPHARMA

  公开号：WO2020062883A1

  公开（公告）日：2020-04-02

  本发明涉及一种基于知母菝契皂苷元结构的衍生物，其结构式如通式I所示，(I) 本发明还提供了上述基于知母菝契皂苷元结构的衍生物的药物组合物及其应用。采用本发明的基于知母菝契皂苷元结构的衍生物、药物组合物及其应用，通过对知母皂苷元结构进行了系统性地修饰和衍生化，结合相关肿瘤细胞抑制活性测试，意外地发现很多衍生化合物具有优越的肿瘤细胞抑制活性，特别是对于多种脑肿瘤细胞的生长有着出乎意料的高抑制活性，对于治疗多种癌症具有潜在的广泛用途和巨大价值，弥补了现有技术在知母皂苷元结构修饰的衍生物的不足，具有重要科学和商业应用价值。
• Oleaginous pharmaceutical and cosmetic foam
  申请人：Tamarkin Dov

  公开号：US20070292461A1

  公开（公告）日：2007-12-20

  The invention relates to stable pharmaceutical or cosmetic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent comprising polyethylene glycol (PEG) or PEG derivative and mixtures thereof, or comprising propylene glycol, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition.